Abstract:Importance: The role of the apolipoprotein E (APOE) ε4 allele as an effect modifier in lifestyle interventions to prevent cognitive impairment is still unclear. Objective: To examine whether the APOE ε4 allele modifies the previously reported significant cognitive benefits of a multidomain lifestyle intervention (prespecified subgroup analysis). Design, setting, and participants: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a randomized clinical trial in 6 centers across Finland (screening and randomization performed from September 7, 2009, through November 24, 2011; intervention duration, 2 years). Data analysis was performed from August 1, 2015, to March 31, 2016. The study population was at-risk older individuals from the general population. Inclusion criteria were age of 60 to 77 years; Cardiovascular Risk Factors, Aging, and Dementia risk score of at least 6 points; and cognition at a mean level or slightly lower than expected for age. Individuals with dementia or substantial cognitive impairment and conditions that prevented cooperation or safe engagement in the intervention were excluded. APOE genotype data were available for 1175 of the 1260 participants. Interventions: Participants were randomly assigned in a 1:1 ratio to a multidomain intervention group (diet, exercise, cognitive training, and vascular risk management) or a control group (general health advice). Group allocation was not actively disclosed to participants, and outcome assessors were masked to group allocation. Main outcomes and measures: Primary outcome was change in cognition measured through a comprehensive neuropsychological test battery. Analysis was based on modified intention to treat (participants with at least 1 postbaseline assessment). Results: A total of 1109 participants (mean [SD] age, 69.3 [4.7] years; 514 [46.3%] female) were included in the analysis: 362 APOE ε4 allele carriers (173 intervention and 189 control) and 747 noncarriers (380 intervention and 367 control). The APOE ε4 carriers and noncarriers were not significantly different at baseline (except for serum cholesterol level). The difference between the intervention and control groups in annual neuropsychological test battery total score change was 0.037 (95% CI, 0.001 to 0.073) among carriers and 0.014 (95% CI, -0.011 to 0.039) among noncarriers. Intervention effect was not significantly different between carriers and noncarriers (0.023; 95% CI, -0.021 to 0.067). Conclusions and relevance: Healthy lifestyle changes may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia. Whether such benefits are more pronounced in APOE ε4 carriers compared with noncarriers should be further investigated. The findings also emphasize the importance of early prevention strategies that target multiple modifiable risk factors simultaneously. Trial registration: ClinicalTrials.gov Identifier: NCT01041989.

No Association Between APOE Genotype and Lipid Lowering with Cognitive Function in a Randomized Controlled Trial of Evolocumab

Regulating Effect of CBF on Memory in Cognitively Normal Older Adults with Different ApoE Genotype: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Cognition after Lowering LDL-Cholesterol with Evolocumab.

Associations Between APOE Genotype and Cerebral Small-Vessel Disease: a Longitudinal Study

APOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial

The Apolipoprotein E Ε4 Allele-Dependent Relationship Between Serum Lipid Levels and Cognitive Function: A Population-Based Cross-sectional Study

Decreased Inter-Hemispheric Functional Connectivity in Cognitively Intact Elderly APOE Ɛ4 Carriers: A Preliminary Study

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial

Abstract 10: Enhanced Benefits of the Life's Essential 8 in APOE Epsilon 4 Carriers

Impact of Lowering LDL-C With Evolocumab on Everyday Cognition in Participants From the FOURIER Trial

P4‐149: Peripheral Apoe Levels Are Associated with Regional Gray Matter Volume, Cerebral Glucose Metabolism and Cognitive Performance in Cognitively Normal APOE E3/4 Carriers

P205: The effect of APOE e4 genotype on cognition, brain volume, glucose metabolism and amyloid deposition in AD

Association of Apolipoprotein E (APOE) Polymorphisms With Serological Lipid and Inflammatory Markers

APOE4 poses opposite effects of plasma LDL on white matter integrity in older adults

Short-term Adverse Effects of the Apolipoprotein E Ε4 Allele over Language Function and Executive Function in Healthy Older Adults.

Higher percent of energy intake as carbohydrates has a negative relationship with cognitive performance in APOE4 carriers

Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study

Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer's Disease

P1‐423: THE EFFECTS OF APOE EPSILON4 ALLELES ON COGNITIVE FUNCTION AND RESTING STATE FUNCTIONAL MRI IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A PROSPECTIVE COHORT STUDY

Effects of Apolipoprotein E4 Genotype on Cerebro-Cerebellar Connectivity, Brain Atrophy, and Cognition in Patients with Alzheimer's Disease